Clinical Trials
6 trialsNCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT03387592 2025-03-10
SENECA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT03963193 2019-05-24
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Henan Cancer Hospital
Phase 2 Unknown
NCT00416767 2016-05-30
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00004922 2013-06-19
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00353015 2012-08-02
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
M.D. Anderson Cancer Center
Phase 2 Completed